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Purpose
The goals of this overview on hereditary hyperekplexia (HPX) caused by dysfunction of glycinergic inhibitory 
transmission are the following.
Goal 1
Describe the clinical characteristics of hereditary hyperekplexia.
Goal 2
Review the genetic causes of hereditary hyperekplexia.
Goal 3
Provide an evaluation strategy to identify the genetic cause of hereditary hyperekplexia in a proband (when 
possible).
Goal 4
Inform genetic counseling of family members of an individual with hereditary hyperekplexia.
Goal 5
Review management of hereditary hyperekplexia.
1. Hereditary Hyperekplexia: Clinical Characteristics
Hereditary hyperekplexia (HPX), an inherited neuronal disorder caused by genetic defects leading to 
dysfunction of glycinergic inhibitory transmission, is characterized by the clinical core features of exaggerated 
startle responses to unexpected sensory stimuli and stiffness. HPX, a rare and underdiagnosed disorder, is 
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manifest immediately after birth and commonly improves with age [Paucar et la 2018]. Establishing the correct 
diagnosis early is essential so that proper management may be initiated to alleviate stiffness and reduce the risk 
of complications, such as potentially life-threatening apnea during episodes of stiffness.
The term hyperekplexia is used to denote excessive or exaggerated startle that typically does not habituate. 
Hyperekplexia can be an acquired feature of many disorders, particularly when there is pontine pathology; it 
may also be observed in infants and children with complex genetic disorders associated with developmental 
delay/intellectual disability often resulting from an inborn error of metabolism or brain malformation (see 
Differential Diagnosis).
HPX Core Features
Excessive startle response (typically eye blinking and a flexor spasm of the trunk) to unexpected, innocuous 
(particularly auditory) stimuli, the most striking feature of HPX, is present from birth or even noted prenatally 
in the last trimester [Thomas et al 2013]. In contrast to a physiologic startle response, the excessive startle leads 
to prolonged stiffening in the neonate and young infant [Gherpelli et al 1995, Vergouwe et al 1997, Koning-
Tijssen & Brouwer 2000]. Consciousness is unaltered during startle responses, and the responses do not 
represent epileptic seizures.
The frequency of startle responses varies considerably among individuals and over time, and often disappears or 
remits with medication between infancy and adolescence [Mine et al 2015].
Factors that increase the frequency of the startle responses include emotional tension (even the expectation of 
being frightened), nervousness, and fatigue. Holding objects or drinking alcohol reduces the intensity and 
frequency of startle responses.
The exaggerated head-retraction reflex (HRR) is an exaggerated startle response to tactile stimuli and is elicited 
by gentle taps particularly to the tip of the nose, but also to the nose ridge, the glabella, upper lip, and chin 
[Wartenberg 1941]. The reaction is non-habituating and comprises neck extension. Note that HRR is not specific 
to HPX and has also been described in acquired hyperekplexia and other disorders.
The excessive startle reflex has major implications for daily life as it cannot be suppressed and unexpected 
stimuli from the outside world cannot be regulated. This is a prominent problem for some infants when the 
simple activities of feeding or being dressed produce paroxysms of startle responses. In later life, the excessive 
startle reflex and associated generalized stiffness increase the risk of falls and injury.
Stiffness. The two main types of stiffness in relation to HPX are generalized continuous stiffness from birth on 
and stiffness induced by startle that may persist into adulthood.
• Generalized stiffness apparent immediately after birth. The stiffness increases with handling and 
disappears during sleep. Held horizontally, the baby is as "stiff as a stick" – therefore, the disorder is also 
called stiff-baby syndrome. The baby is alert but shows few spontaneous movements [Koning-Tijssen & 
Brouwer 2000]. Handling a baby, for example when changing diapers, is difficult because spreading of the 
legs is limited by stiffness.
The generalized stiffness evident immediately after birth usually normalizes during the first years of life 
(by age 2 years; range: 0.7-5 years) [Mine et al 2015].
• Generalized stiffness following the startle response means that for a short period, affected individuals 
become stiff and voluntary movements are impossible [Bernasconi et al 1996]. Startled individuals may 
fall "like a log," with the stiffness preventing them from putting out their arms to safeguard themselves, 
resulting in an increased risk of injuries [Tijssen et al 2002, Thomas et al 2013, Mine et al 2015, Lee et al 
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2017]. This may persist into adult life. Affected individuals may have a cautious, stiff-legged, broad-based 
gait (but without signs of ataxia; see video at Zhang et al [2019]; full text).
Other complications of severe attacks of stiffness:
• Episodes of tonic neonatal cyanosis (i.e., attacks of apnea in neonates with HPX) [Vergouwe et al 1997, 
Miraglia Del Giudice et al 2003, Rees et al 2006, Rivera et al 2006]. Akin to the generalized stiffness, 
attacks of tonic neonatal cyanosis often resolve during infancy [Rees et al 2006]. The association with 
sudden infant death syndrome underlines the importance of early diagnosis and treatment [Nigro & Lim 
1992].
• Frequent occurrence of inguinal, umbilical, or epigastric hernias, paralytic ileus, and congenital 
dislocation of the hip [Mine et al 2015]
Associated features that may be present include the following:
• In some children, delayed motor milestones and mild developmental delay or learning difficulties 
(particularly speech acquisition); children later catch up [Thomas et al 2013].
• Periodic limb movements in sleep (PLMS) and hypnagogic myoclonus (myoclonus occurring when falling 
asleep)
• Epilepsy; estimated prevalence in hyperekplexia of 7%-12% [Thomas et al 2013]
Differential Diagnosis
The differential diagnosis of abnormal startle can be divided into the following:
• Conditions with an abnormal, exaggerated startle including:
⚬ Complex genetic neurodevelopmental disorders
⚬ Acquired causes
Note: It is this group of disorders that is most likely to be confused with hereditary hyperekplexia resulting 
from dysfunction of glycinergic inhibitory transmission.
• Conditions in which the startle response per se is normal, but the startle is triggering the actual disease-
defining symptoms
• Neuropsychiatric syndromes, in which startle may be excessive and can be followed by additional 
manifestations
Conditions with an Abnormal, Exaggerated Startle
Complex genetic neurodevelopmental disorders in which an excessive startle response in infants and children 
can be associated with developmental delay/intellectual disability often resulting from an inborn error of 
metabolism or brain malformation (with or without microcephaly and/or epilepsy) (Table 1) are distinct from 
hereditary hyperekplexia and will not be discussed further in this overview.
Table 1. Complex Genetic Neurodevelopmental Disorders with an Excessive Startle Response
Gene Disorder MOI Distinguishing Clinical Features Reference 1
ARHGEF9 Early-infantile epileptic encephalopathy 8 XL
• Severe ID
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Table 1. continued from previous page.
Gene Disorder MOI Distinguishing Clinical Features Reference 1
ASNS Asparagine synthetase deficiency AR
• Profound DD & progressive encephalopathy
• Microcephaly




CACNA1A Early-infantile epileptic encephalopathy 42 AD
• Epileptic encephalopathy w/myoclonic 
epilepsy
• Myoclonic seizures provoked by tactile stimuli 
& spontaneous & reflex seizures to noise & 
touch
OMIM 617106
CLPB CLPB deficiency (3-methylglutaconic aciduria) AR
• Congenital or infantile cataracts
• Neutropenia
• Other neurologic signs: hypotonia, spasticity, 
ataxia, dystonia, epilepsy, or ID
CLPB Deficiency




CTNNB1 CTNNB1-related syndrome AD
• Hyperekplexia is rare in this entity (single case 
report)
• Later onset of hyperekplexia (not congenital 
but in childhood) & atypical pattern (no 
generalized stiffness induced by startle)
• No congenital stiffness
• Progressive neurologic involvement w/
additional signs (ID, ataxia, spasticity)
• Microcephaly








• Severe psychomotor retardation
• Hypotonia combined w/hyperreflexia
• Usually lethal in infancy
OMIM 615501
HEXA Tay-Sachs disease AR
• DD or regression
• Visual impairment
• Epilepsy
• Later: macrocephaly, decerebrate posturing, 




RPS6KA3 Coffin-Lowry syndrome XL
• ID
• Facial dysmorphism, tapering digits, & skeletal 
deformity
• Besides hyperekplexia, there may be other 
types of stimulus-induced drop attacks (e.g., 
cataplexy-like episodes)
Coffin-Lowry Syndrome
SCN8A Early-infantile epileptic encephalopathy 13 AD Epileptic encephalopathy w/DD & ID
SCN8A-Related Epilepsy 
with Encephalopathy
SLC6A9 GLYT1 encephalopathy AR







Table 1. continued from previous page.
Gene Disorder MOI Distinguishing Clinical Features Reference 1
SUOX Isolated sulfite oxidase deficiency AR
• Progressive epileptic encephalopathy
• Other neurologic features: opisthotonus, 
spastic quadriplegia, pyramidal signs.
• Microcephaly, dysmorphic features
Isolated Sulfite Oxidase 
Deficiency
TRAK1 Early-infantile epileptic encephalopathy 68 AR
• Hypotonia
• Progressive epileptic encephalopathy OMIM 618201
TSEN54 Pontocerebellar hypoplasia type 2 AR
• Generalized clonus ("jitteriness")
• Delayed developmental (motor & cognitive) 
milestones





AD = autosomal dominant; AR = autosomal recessive; DD = developmental delay; ID = intellectual disability; MOI = mode of 
inheritance; XL = X-linked
1. OMIM phenotype entry or citation is provided if a related GeneReview is not available
Acquired causes of excessive startle
• Structural and other causes of brain stem dysfunction can include post-anoxic reticular myoclonus, 
infarct, hemorrhage, medullary compression, posterior fossa malformations, neurodegeneration 
(multisystem atrophy, lateral sclerosis), and infectious or autoimmune encephalitis (reviewed in Balint et 
al [2018]) including multiple sclerosis [Abboud et al 2019].
• Infection. The most important infectious cause is tetanus, a potentially lethal disorder caused by the toxin 
of Clostridium tetani which degrades synaptobrevin and thereby prevents neurotransmitter release for 
glycinergic inhibition. The latter is the common end route with HPX, explaining the phenotypic 
similarities.
• Glycine receptor antibodies (targeting the same protein affected by pathogenic variants in GLRA) are an 
autoimmune cause of exaggerated startle and stiffness [Hutchinson et al 2008] and may manifest as brain 
stem encephalitis or a variant of stiff person spectrum disorder (SPSD), such as progressive 
encephalomyelitis with rigidity and myoclonus [Balint & Bhatia 2016]. However, SPSD is also seen with 
glutamic acid decarboxylase, amphiphysin, or DPPX antibodies. They share as core features stiffness, 
spasms, and hyperekplexia (in varying degrees and body distribution). Onset is typically in adulthood, 
although infantile onset has been described by Damásio et al [2013]. Other features distinguishing SPSD 
from HPX are the mostly continuous and prominent muscle stiffness, sometimes co-occurring neurologic 
signs, and often a strong association with other autoimmune diseases.
• Strychnine is a competitive inhibitor of the postsynaptic glycine receptor. Strychnine poisoning causes 
acute onset of stiffness, spasms, and hyperekplexia.
Startle-Induced Manifestations in Other Disorders
In this diverse group of disorders, the startle reflex itself is not excessive, but rather induces another clinical 
feature that is more prominent and characteristic than the startle response [Dreissen & Tijssen 2012]. Examples 
include the following:
• Startle epilepsy (normal startle triggers seizures)
• Paroxysmal kinesigenic choreoathetosis (See PRRT2-Associated Paroxysmal Movement Disorders; startle 
can be one of many triggers of sudden movements.)
• Creutzfeldt-Jakob disease (see Genetic Prion Disease)
• Subacute sclerosing panencephalitis
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Neuropsychiatric Startle Syndromes
In addition to excessive startling, behavioral and/or psychiatric findings are observed in the following groups of 
disorders:
• Culture-specific syndromes, in which an exaggerated startle response, evoked by auditory, sensory, or 
visual stimuli occurs within a community [Meinck 2006]. The initial brief component of the startle reflex 
is normal, but the secondary orientating response includes abnormal behaviors such as jumps, echopraxia, 
or echolalia, spontaneous vocalizations including coprolalia, and automatic execution when startled with 
vigorous commands ("forced obedience").
• Anxiety disorders, functional neurologic disorders
• Tics and Gilles de la Tourette syndrome, in which an exaggerated startle reflex has been described in 
some, but not all, affected individuals
2. Hereditary Hyperekplexia: Causes
To date, three genes are known to be associated with hereditary hyperekplexia (HPX): GLRA1, GLRB, and 
SLC6A5. Genetic defects in these genes result in dysfunction of glycinergic inhibitory transmission. The relative 
contribution of each of these three genes to HPX (based on data on 97 individuals with confirmed GLRA1-, 
GLRB-, or SLC6A5-HPX [Thomas et al 2013]), the modes of inheritance, and methods of pathogenic variant 
detection are summarized in Table 2.
Table 2. GLRA1, GLRB, and SLC6A5-Related Hereditary Hyperekplexia: Modes of Inheritance and Methods of Variant Detection
Gene
Proportion of HPX 
Attributed to Mutation of 
Gene
MOI 1
Proportion of Probands with a Pathogenic Variant 
Detectable by Method 2
Sequence analysis 3 Gene-targeted deletion/duplication analysis 4
GLRA1 61%-63% AD & AR ~95% See footnote 5
GLRB 12%-14% AD & AR 11/12 1/12 6
SLC6A5 25% AR (rarely AD 7) 24/24 None reported
AD = autosomal dominant; AR = autosomal recessive; HPX = hereditary hyperekplexia; MOI = mode of inheritance
1. ~85% were AR and ~15% were AD [Thomas et al 2013].
2. Since the study of Thomas et al [2013], additional affected individuals have been reported, many as case studies. For additional 
reported variants, see Human Genome Mutation Database [Stenson et al 2017].
3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. 
Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon 
or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
4. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative 
PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect 
single-exon deletions or duplications
5. Deletion of exons 1 through 7 is common in the Turkish population [Thomas et al 2015]. Deletion of exons 1 through 6 [Brune et al 
1996] and of 4 through 7 have also been reported [Chung et al 2010].
6. Chung et al [2013]
7. Rees et al [2006]
Phenotype Correlations by Gene
The following were observed in the study of Thomas et al [2013]:
• Individuals with GLRB-HPX or SLC6A5-HPX were more likely to have developmental delay (RR1.5 
P<0.01; RR1.9 P<0.03) than those with GLRA1-HPX, whereas 92% of individuals reported with GLRB-
HPX had mild-to-severe delay in speech acquisition.
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• Children with SLC6A5-HPX were significantly more likely to have had recurrent infantile apnea (RR1.9; 
P<0.005) than those with GLRA1-HPX.
• Individuals without a molecularly confirmed diagnosis of HPX compared to those with a molecular 
diagnosis were more likely to have first clinical manifestations after age one month (P<0.001). In contrast, 
the characteristic "stiffness, startles, and stumbles" of hyperekplexia, apnea attacks (50 of 89), and delayed 
development (47 of 92) were frequently reported in both groups.
• Individuals with a molecularly confirmed diagnosis of HPX typically are not dysmorphic and brain 
imaging reveals a structurally normal brain.
3. Hereditary Hyperekplexia: Evaluation Strategy to Identify the 
Genetic Cause in a Proband
Establishing a specific genetic cause of HPX can aid genetic counseling (see Section 4). Establishing the genetic 
cause of HPX in a proband usually involves family history and genomic/genetic testing.
Family history. A three-generation family history should be obtained, with attention to relatives with HPX and 
documentation of relevant findings through direct examination or review of medical records including results of 
molecular genetic testing. Identify "sudden infant deaths" that may have been caused by apnea.
Molecular genetic testing approaches can include a combination of gene-targeted testing (multigene panel or 
single-gene testing) and comprehensive genomic testing (exome sequencing, exome array, or chromosomal 
microarray analysis [CMA]). Some pathogenic variants are more common in some geographic regions and 
ethnic groups [Thomas et al 2015]. Gene-targeted testing requires the clinician to hypothesize which gene(s) are 
likely involved, whereas genomic testing does not.
• Serial single-gene testing can be considered if family history indicates that pathogenic variants in a 
particular gene are most likely (see Table 2). Sequence analysis detects small intragenic deletions/
insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/
duplications are not detected. Perform sequence analysis in the following order: GLRA1, SLC6A5, and 
GLRB. If no pathogenic variant is found, perform gene-targeted deletion/duplication analysis to detect 
intragenic deletions or duplications.
• A multigene panel that includes GLRA1, GLRB, and SLC6A5 is most likely to identify the genetic cause of 
the condition at the most reasonable cost while limiting identification of variants of uncertain significance 
and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes 
included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory 
and are likely to change over time. (2) Some multigene panels may include genes not associated with the 
condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom 
laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified 
by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, 
and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/
duplication analysis is recommended (see Table 2).
For an introduction to multigene panels click here. More detailed information for clinicians ordering 
genetic tests can be found here.
• Comprehensivegenomic testing does not require the clinician to determine which gene[s] are likely 
involved. Exome sequencing is most commonly used; genome sequencing is also possible. If exome 
sequencing is not diagnostic, exome array (when clinically available) may be considered to detect 
(multi)exon deletions or duplications that cannot be detected by sequence analysis.
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For an introduction to comprehensive genomic testing click here. More detailed information for clinicians 
ordering genomic testing can be found here.
4. Hereditary Hyperekplexia: Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, 
and implications of genetic disorders to help them make informed medical and personal decisions. The following 
section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for 
family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may 
face or to substitute for consultation with a genetics professional. —ED.
Mode of Inheritance
GLRA1- and GLRB-related hereditary hyperekplexia (HPX) can be inherited in an autosomal recessive or, less 
commonly, an autosomal dominant manner (Table 2). SLC6A5-HPX is inherited in an autosomal recessive 
manner (autosomal dominant inheritance of SLC6A5-HPX has been reported in one family). General genetic 
counseling issues regarding autosomal dominant and recessive inheritance are discussed in this section.
Autosomal Recessive Inheritance
Risk to Family Members
Parents of a proband
• The parents of a child with autosomal recessive HPX are obligate heterozygotes (i.e., presumed to be 
carriers of one GLRA1, GLRB, or SLC6A5 pathogenic variant based on family history).
• Molecular genetic testing is recommended for the parents of a proband to confirm that each parent is 
heterozygous for an autosomal recessive HPX-causing pathogenic variant and to allow reliable recurrence 
risk assessment. (De novo variants are known to occur at a low but appreciable rate in autosomal recessive 
disorders [Jónsson et al 2017].)
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing hyperekplexia.
Sibs of a proband
• If each parent is known to be heterozygous for an autosomal recessive HPX-causing pathogenic variant, 
each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being 
an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.
Offspring of a proband. The offspring of an individual with autosomal recessive HPX are obligate heterozygotes 
(carriers) for a pathogenic variant.
Carrier (Heterozygote) Detection
Carrier testing for at-risk relatives requires prior identification of the pathogenic variants in the family.
Autosomal Dominant Inheritance – Risk to Family Members
Parents of a proband
• Most individuals diagnosed with autosomal dominant HPX have an affected parent.
• In rare cases, an individual diagnosed with autosomal dominant HPX has the disorder as the result of a de 
novo GLRA1 or GLRB pathogenic variant [Miraglia Del Giudice et al 2003, James et al 2013, Horváth et al 
2014].
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• Molecular genetic testing is recommended for the parents of a proband with an apparent de novo 
pathogenic variant.
• If the pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, the 
proband most likely has a de novo pathogenic variant; another possible explanation is germline mosaicism 
in a parent (though theoretically possible, no instances of parental germline mosaicism have been 
reported).
Sibs of a proband. The risk to the sibs of the proband depends on the clinical/genetic status of the proband's 
parents:
• If a parent of the proband is affected and/or is known to have the pathogenic variant identified in the 
proband, the risk to the sibs of having the same pathogenic variant is 50%. However, because autosomal 
dominant hereditary hyperekplexia is not 100% penetrant, sibs who inherit a pathogenic variant may or 
may not manifest features of HPX [Sprovieri et al 2019].
• If the proband has a known pathogenic variant that cannot be detected in the leukocyte DNA of either 
parent, the recurrence risk to sibs is estimated to be 1% because of the theoretic possibility of parental 
germline mosaicism [Rahbari et al 2016].
• If the parents have not been tested for the pathogenic variant but are clinically unaffected, the risk to the 
sibs of a proband appears to be low. However, sibs of a proband with clinically unaffected parents are still 
presumed to be at increased risk for hereditary hyperekplexia because of the possibility of reduced 
penetrance in a heterozygous parent or the theoretic possibility of parental germline mosaicism.
Offspring of a proband. Each child of an individual with autosomal dominant HPX has a 50% chance of 
inheriting the pathogenic variant.
Other family members. The risk to other family members depends on the status of the proband's parents: if a 
parent is affected, his or her family members may be at risk.
Prenatal Testing and Preimplantation Genetic Testing
Once the HPX-causing pathogenic variant(s) have been identified in an affected family member, prenatal testing 
for a pregnancy at increased risk and preimplantation genetic testing are possible.
Differences in perspective may exist among medical professionals and within families regarding the use of 
prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather 
than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of 
the parents, discussion of these issues is appropriate.
5. Hereditary Hyperekplexia: Management
Treatment of Manifestations
Clonazepam is the treatment of choice for HPX [Tijssen et al 1997, Tsai et al 2004, Thomas et al 2013, Mine et al 
2015]. The stiffness in the neonatal period and stiffness related to startle diminish with the treatment. Suggested 
daily doses are 0.01 to 0.1 mg/kg for children and 0.8 mg/kg for adults [Mine et al 2015].
Other drugs, mostly described in case reports, which have shown variable results include: carbamazepine, 
clobazam, phenytoin, diazepam, valproate, 5-hydroxytryptophan, piracetam, and phenobarbital. For an 
overview see Bakker et al [2006].
Physical and cognitive therapy to reduce the fear of falling and thereby improve walking can be considered; no 
randomized trials have assessed the effectiveness of such treatment.
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Attacks of tonic neonatal cyanosis can be stopped by the Vigevano maneuver, consisting of forced flexion of the 
head and legs towards the trunk [Vigevano et al 1989].
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries 
for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the 
information provided by other organizations. For information on selection criteria, click here.
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